IPH 1101: Interim Phase I/II data

Interim data from the European Phase I/II IPH 1101-202 trial in 34 evaluable follicular NHL patients who have relapsed after >=1 course of treatment with rituximab showed that IPH 1101 plus low-dose interleukin-2 (IL-2) and rituximab led to an ORR of 47%, including 11 complete responses and 5 partial responses, plus 15 cases of stable disease. The trial has enrolled 45 patients. Data were presented at the American Society of Hematology meeting in New Orleans. Innate previously reported data from 16 evaluable patients in the trial (see BioCentury, Oct. 5). ...